1. U.S. Food and Drug Administration (2010). Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling.
2. U.S. Food and Drug Administration (2020). Draft Guidance, Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling.
3. European Medicines Agency (2015). Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function, European Medicines Agency.
4. Design and conduct considerations for studies in patients with impaired renal function;Ravenstijn;Clin. Transl. Sci.,2021
5. Modeling and predicting drug pharmacokinetics in patients with renal impairment;Yeo;Expert Rev. Clin. Pharmacol.,2011